B7-H3 in acute myeloid leukemia:From prognostic biomarker to immunotherapeutic target  

作　　者：Xiao Tan Xiangyu Zhao 

机构地区：[1]Peking University People’s Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,Beijing 100044,China

出　　处：《Chinese Medical Journal》2024年第21期2540-2551,共12页中华医学杂志(英文版)

基　　金：supported by grants from the National Natural Science Foundation of China(Nos.82070184 and 82270228);Beijing Nova Program(No.20220484235);Peking University People’s Hospital Research and Development Funds(No.RDL2021-01).

摘　　要：B7-H3(CD276),an immune checkpoint protein of the B7 family,exhibits significant upregulation in solid tumors and hematologic malignancies,exerting a crucial role in their pathophysiology.The distinct differential expression of B7-H3 between tumors and normal tissues and its multifaceted involvement in tumor pathogenesis position it as a promising therapeutic target for tumors.In the context of acute myeloid leukemia(AML),B7-H3 is prominently overexpressed and closely associated with unfavorable prognoses,yet it has remained understudied.Despite various ongoing clinical trials demonstrating the potential efficacy of immunotherapies targeting B7-H3,the precise underlying mechanisms responsible for B7-H3-mediated proliferation and immune evasion in AML remain enigmatic.In view of this,we comprehensively outline the current research progress concerning B7-H3 in AML,encompassing in-depth discussions on its structural attributes,receptor interactions,expression profiles,and biological significance in normal tissues and AML.Moreover,we delve into the protumor effects of B7-H3 in AML,examine the intricate mechanisms that underlie its function,and discuss the emerging application of B7-H3-targeted therapy in AML treatment.By juxtaposing B7-H3 with other molecules within the B7 family,this review emphasizes the distinctive advantages of B7-H3,not only as a valuable prognostic biomarker but also as a highly promising immunotherapeutic target in AML.

关 键 词：B7-H3(CD276) B7 family Acute myeloid leukemia Immune checkpoint IMMUNOTHERAPY 

分 类 号：R73[医药卫生—肿瘤]